Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor
Sponsor: ImmuneOncia Therapeutics Inc.
Summary
The goal of this clinical trial is to determine the efficacy of IMC-001 in metastatic or locally advanced TMB-H solid tumor patients.
Official title: PHASE 2 STUDY OF IMC-001 IN PATIENTS WITH METASTATIC OR LOCALLY ADVANCED TMB-H SOLID TUMOR
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2025-01-13
Completion Date
2029-08
Last Updated
2026-04-17
Healthy Volunteers
No
Interventions
IMC-001
All participants will receive the study drug, IMC-001, at 20 mg/kg Q2W via IV infusion over 60 minutes.
Locations (4)
National Cancer Center
Goyang, South Korea
Seoul National University Bundang Hospital
Seongnam, South Korea
Samsung Medical Center
Seoul, South Korea
Severance Hospital
Seoul, South Korea